IMP7068 — Investigational Agent
Other · Phase 1 · Antengene / Impact Therapeutics
Mechanism of Action
IMP7068 is a highly selective oral WEE1 kinase inhibitor that abrogates the G2/M cell-cycle checkpoint, forcing DNA-damaged and p53-deficient tumor cells into premature mitosis and mitotic catastrophe.
Investigational Indications
- Platinum-resistant ovarian cancer
- Uterine serous carcinoma
- TP53-mutant advanced solid tumors